M
Marcin Hachuła
Researcher at Medical University of Silesia
Publications - 11
Citations - 41
Marcin Hachuła is an academic researcher from Medical University of Silesia. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.
Papers
More filters
Journal ArticleDOI
The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.
Michał Kosowski,Joanna Smolarczyk-Kosowska,Marcin Hachuła,Mateusz Maligłówka,Marcin Basiak,Grzegorz Machnik,Robert Pudlo,Bogusław Okopień +7 more
TL;DR: A review of the literature describing the impacts of statins on dopamine, serotonin, acetylcholine, and glutamate neurotransmission, as well as their neuroprotective role is presented in this paper.
Journal ArticleDOI
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka,Michał Kosowski,Marcin Hachuła,Marcin Cyrnek,Łukasz Bułdak,Marcin Basiak,Aleksandra Bołdys,Grzegorz Machnik,Rafał J. Bułdak,Bogusław Okopień +9 more
TL;DR: Current knowledge on the roles that PCSK9 plays in different tissues and perspectives for its clinical use are summarized.
Journal ArticleDOI
Plasma Concentrations of Cytokines in Patients with Combined Hyperlipidemia and Atherosclerotic Plaque before Treatment Initiation—A Pilot Study
TL;DR: Levels of lipid panel, IL-6 and IL-18 were significantly lower in the group of healthy people than in the study group, suggesting that these cytokines as a panel might be used as new indicators of the presence of unstable atherosclerotic plaque.
Journal ArticleDOI
Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
TL;DR: The findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits in patients who are statin-intolerant or contraindicated to statin use.
Journal ArticleDOI
Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
TL;DR: The study’s results suggest that PCSK-9 inhibitor therapy significantly reduces the concentration of factors influencing the stability of atherosclerotic plaque, which may explain their essential importance in reducing cardiovascular risk in patients receiving this treatment.